New combo therapy targets hard-to-treat lymphomas in early trial
NCT ID NCT07339527
First seen Jan 15, 2026 · Last updated Jun 14, 2026 · Updated 30 times
Summary
This study tests a new drug, zeprumetostat, combined with other treatments for people whose T-cell or NK-cell lymphoma has come back or stopped responding to therapy. The goal is to find safe doses and see if the combination shrinks tumors. About 60 adults will take part in this early-phase trial across multiple hospitals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MATURE T-CELL AND NK-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.